


## Diphenyleneiodonium chloride

Cat. No.:	HY-100965		
CAS No.:	4673-26-1		
Molecular Formula:	C <sub>12</sub> H <sub>8</sub> ClI		
Molecular Weight:	314.55		
Target:	TRP Channel; NADPH Oxidase		
Pathway:	Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 6 mg/mL (19.07 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.1791 mL	15.8957 mL	31.7915 mL
	5 mM	0.6358 mL	3.1791 mL	6.3583 mL
	10 mM	0.3179 mL	1.5896 mL	3.1791 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Diphenyleneiodonium chloride is a **NADPH oxidase (NOX)** inhibitor and also functions as a **TRPA1** activator with an EC<sub>50</sub> of 1 to 3 μM.

#### IC<sub>50</sub> & Target

NOX<sup>[1]</sup>  
EC<sub>50</sub>: 1 to 3 μM (TRPA1)<sup>[1]</sup>

#### In Vitro

Diphenyleneiodonium chloride is a NADPH oxidase (NOX) inhibitor and also functions as a TRPA1 activator with an EC<sub>50</sub> of 1 to 3 μM. Application of Diphenyleneiodonium chloride to HEK-TRPA1 cells at a concentration ranges of 0.03 to 10 μM effectively induces a Ca<sup>2+</sup> response. However, Diphenyleneiodonium chloride fails to evoke a Ca<sup>2+</sup> response in control HEK cells, even at a relatively high dose of 10 μM<sup>[1]</sup>. When Diphenyleneiodonium chloride is included in the co-cultures, lipopolysaccharide (LPS)-induced preOL apoptosis is significantly inhibited. Treatment with Diphenyleneiodonium chloride is found to significantly attenuate the LPS-induced O<sub>2</sub><sup>-</sup> production by 2.0-fold, reducing it to within 27% of the controls<sup>[2]</sup>.

## In Vivo

Intraplantar injection of 2 mM Diphenyleneiodonium chloride to the hindpaw causes licking or biting behavior<sup>[1]</sup>. Diphenyleneiodonium chloride treatment immediately or 24 h after lipopolysaccharide (LPS) injection significantly attenuates the LPS-induced loss of O4 positive cells. Treatment with Diphenyleneiodonium chloride either immediately or 24 h after LPS injection significantly ameliorates the LPS-induced disorganization of the white matter nerve fibers. However, treatment with DPI 48 h after LPS injection does not appear to correct the LPS-induced white matter damage. DPI treatment either immediately or 24 h after LPS injection significantly reduces the accumulation of both gp91phox and p67phox in the membrane fraction<sup>[2]</sup>.

## PROTOCOL

### Cell Assay <sup>[2]</sup>

Purified **microglia** and preOLs are co-cultured using a Transwell culture system. Co-cultured cells are divided into three groups: control, lipopolysaccharide (LPS)-activated, and LPS plus Diphenyleneiodonium chloride. Microglia are cultured in Transwells over established preOL layers and exposed to either LPS (100 ng/mL), LPS+ **Diphenyleneiodonium chloride (10 μM)** or untreated. The medium supernatants and cellular protein fractions from the co-cultures are then collected for further analysis after 48 h incubation<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration <sup>[1]</sup>

The **ddy mice** (6 to 7 wk of age) are individually placed in transparent cages for 30 min before experiments. An **intraplantar injection of 10 μL Diphenyleneiodonium chloride (2 mM, solvent: Kolliphor EL with 20% DMSO)** is then injected into the right hindpaw with or without intraperitoneal administration with HC030031 (300 mg/kg at 0.5 h prior to injection of Diphenyleneiodonium chloride; solvent: saline with 0.5% methyl cellulose). The time spent licking or biting the injected paw is recorded for 45 min after injection<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- **Toxicol Appl Pharmacol.** 2019 Mar 1;366:83-95.
- **Am J Physiol Heart Circ Physiol.** 2018 Mar 1;314(3):H580-H592.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Suzuki H, et al. The NADPH oxidase inhibitor diphenyleneiodonium activates the human TRPA1 nociceptor. *Am J Physiol Cell Physiol.* 2014 Aug 15;307(4):C384-94.

[2]. He YF, et al. Diphenyleneiodonium protects preoligodendrocytes against endotoxin-activated microglial NADPH oxidase-generated peroxynitrite in a neonatal rat model of periventricular leukomalacia. *Brain Res.* 2013 Jan 25;1492:108-21.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA